Depression: Causes, Treatment, and Stigma

Introduction

Depression is often discussed as if its causes, treatments, and social stigma were separate issues, but that separation weakens both understanding and response. A useful account of depression must connect biological vulnerability, clinical symptoms, life stress, access to care, treatment effectiveness, and the social meanings attached to mental illness. Treatment matters, but symptom reduction alone does not address why depression develops, why some people are not identified early, why others do not respond to first-line care, or why many delay help because of shame or fear of judgment. This essay argues that depression is best understood as an interacting biological, clinical, psychosocial, and stigma-shaped condition. Its burden therefore requires prevention, early detection, individualized stepped care, stronger options for treatment-resistant depression, and stigma reduction. Addressing these dimensions together offers a more realistic framework than treating depression as only a private illness or only a medical problem.

Prevalence and Public Burden

Depression’s public importance begins with its scale, but the scale looks different depending on what researchers count. Diagnostic estimates show a substantial baseline burden: annual major depressive episode prevalence among U.S. adults is reported at 7.1%, and global estimates place major depressive disorder at more than 300 million people, or 4.4% of the world population (Zhdanava et al., 2021; Chodavadia et al., 2023). Symptom-based studies suggest an even wider reach, especially during COVID-19. In nationally representative U.S. survey data, clinically significant depression symptoms rose from 8.5% before COVID-19 to 27.8% during the early pandemic, while a Singapore web-panel study found that 14.1% of adults screened positive for depression symptoms and roughly half of those with depression had never been formally diagnosed (Ettman et al., 2020; Chodavadia et al., 2023). These figures support treating depression as common, but not all estimates mean the same thing: screeners measure symptom burden, whereas diagnosis requires clinical assessment.

The burden of depression is also social and economic, not only personal distress. Depression is identified as a leading contributor to mental-health disease burden, and the World Health Organization has ranked it as the largest contributor to global disability, accounting for 7.5% of years lived with disability in 2015 (Pearce et al., 2022; Chodavadia et al., 2023). Economic estimates show why this matters for policy. Chodavadia et al. (2023) estimated the annual burden of depression and anxiety symptoms in Singapore at SGD 15.7 billion, with most of the cost coming from presenteeism rather than direct health care. U.S. claims-based modeling similarly estimated $45.5 billion in annual incremental health-care costs for medication-treated major depressive disorder, with treatment-resistant depression adding especially high direct and indirect costs (Zhdanava et al., 2021; McIntyre et al., 2023). Because these estimates depend on claims data, productivity assumptions, and inconsistent definitions of treatment resistance, they should be read as strong evidence of burden rather than as interchangeable totals.

Interacting Causes and Risk Conditions

The prevalence patterns discussed above matter because depression risk is clustered by social position and exposure to stress, not distributed randomly. Economic insecurity appears especially important: in U.S. pandemic survey data, adults in the lowest income group had more than twice the adjusted odds of depression symptoms compared with those earning $75,000 or more, and people with fewer savings also had elevated risk (Ettman et al., 2020). Stress exposure added another layer, with high COVID-19 stressor exposure associated with roughly triple the odds of depression symptoms compared with low exposure (Ettman et al., 2020). Childhood adversity deepens this pattern because emotional abuse and early trauma are linked to recurrent depression, persistent depression, and poorer antidepressant response (McIntyre et al., 2023). This does not mean poverty alone explains depression; one Singapore study found a higher-income symptom-reporting subsample, while also cautioning that online panel participation may limit representativeness (Chodavadia et al., 2023). The stronger conclusion is that disadvantage, stress, and trauma interact to concentrate risk.

Biological and clinical contributors also show why depression cannot be reduced to one cause or one pathway. Major depressive disorder involves mood and cognitive changes and loss of interest or pleasure lasting at least two weeks, but patients differ widely in severity, duration, symptoms, and comorbidities (Zhdanava et al., 2021; McIntyre et al., 2023). Those differences matter clinically. Greater baseline severity and longer depressive episodes are repeatedly associated with treatment-resistant depression, while anxious depression, cognitive symptoms, psychotic symptoms, and physical comorbidities can further complicate response (McIntyre et al., 2023). Comorbidity is not marginal: in Singapore, 66.0% of respondents with depression symptoms also had anxiety symptoms (Chodavadia et al., 2023). Sex differences add another layer, since women showed higher symptom prevalence than men in U.S. pandemic data, although female sex itself is not clearly established as an independent risk factor for treatment resistance (Ettman et al., 2020; McIntyre et al., 2023). Depression therefore reflects interacting vulnerabilities rather than a single biological defect.

Prevention and Detection Gaps

Because depression risk is shaped by social stress and limited resources, an effective response has to begin before crisis-level treatment. Prevention evidence supports this shift: Pearce et al. (2022) found that physical activity was linked to lower depression risk even below standard public-health targets, with adults doing half the recommended amount showing an 18% lower risk than inactive adults. That finding should not be overstated, because the review reported substantial heterogeneity and diminishing certainty beyond recommended activity levels; still, it shows that prevention can include realistic, modifiable protective factors rather than only clinical intervention after symptoms worsen (Pearce et al., 2022). The larger problem is that many people never reach timely care. Studies report a large treatment gap, with many adults undiagnosed, outside formal care, or inaccurately diagnosed, including cases where apparent antidepressant resistance may reflect bipolar disorder rather than major depressive disorder (Samari et al., 2022; Chodavadia et al., 2023; McIntyre et al., 2023). Prevention and detection therefore belong at the front of depression care.

Treatment Pathways and Resistance

Because depression arises from interacting clinical and biological risk conditions, treatment has to be staged rather than one-size-fits-all. Standard care begins with accurate assessment and an adequate therapeutic trial, then moves to dose optimization, switching, combination treatment, augmentation, psychotherapy, or somatic treatment when symptoms persist. McIntyre et al. (2023) note that an adequate antidepressant trial is generally 4–6 weeks at optimal dosing, although some patients require longer, and they also argue that clinically useful definitions of resistance should include nonresponse to psychotherapy because psychotherapy is first-line for mild to moderate depression. After inadequate response, Ruberto et al. (2020) identify the main next steps as optimizing the current dose, switching antidepressants, combining antidepressants, or augmenting with a non-antidepressant medication. This pathway supports evidence-based care, but it also requires shared decision-making because each step trades possible benefit against side effects, discontinuation risk, and loss of partial improvement.

The difficulty is that staged care does not guarantee remission in real-world practice. Persistent symptoms remain common even after evidence-based antidepressant treatment, and one review reports that up to 70% of people continue to experience burdensome symptoms despite such treatment (Ruberto et al., 2020). Treatment resistance is usually defined as failure to respond or remit after at least two adequate antidepressant trials, but that definition is unstable across studies and can blur true resistance with pseudo-resistance caused by misdiagnosis, inadequate trials, inaccurate response assessment, or nonadherence (Zhdanava et al., 2021; McIntyre et al., 2023). This qualification matters because adherence itself is a major clinical barrier: about 30% to 50% of people prescribed antidepressants are nonadherent during acute-phase treatment (McIntyre et al., 2023). The result is not that treatment fails, but that treatment systems must distinguish nonresponse from incomplete or poorly matched care.

For patients with genuine treatment-resistant depression, stronger options exist, but the evidence is uneven and the burden is disproportionate. Pharmacological reviews support ketamine and esketamine, and certain second-generation antipsychotic augmentations such as aripiprazole or quetiapine can outperform switching for some patients (Ruberto et al., 2020; McIntyre et al., 2023). Neurostimulation also expands the treatment pathway: electroconvulsive therapy is regarded as effective for acute and maintenance treatment-resistant depression, repetitive transcranial magnetic stimulation is FDA-approved and supported by reviews, and vagus nerve stimulation has evidence for higher-order resistance (McIntyre et al., 2023). Yet these options do not erase uncertainty, because evidence for switching, extending trials, and combining antidepressants remains mixed, and some augmentations carry metabolic or tolerability risks (Ruberto et al., 2020; McIntyre et al., 2023). This subgroup therefore deserves special attention: treatment-resistant depression represents less than a third of medication-treated MDD but accounts for a majority of its incremental health-care cost difference (Zhdanava et al., 2021).

Stigma and Access Interventions

Stigma is not a side issue in depression care because it can block disclosure before formal treatment is even considered. Although people with depressive disorders often prefer to seek help first from family and friends, those informal networks can respond with absence of support, unhelpful advice, pressure not to disclose, or opposition to professional help (Samari et al., 2022). That finding complicates the assumption that social support naturally improves access: family and peers may be a bridge to care, but they can also become the first point where shame is reinforced. Survey evidence points in the same direction, since stigma and social desirability can reduce willingness to disclose symptoms, especially in face-to-face settings (Chodavadia et al., 2023). This helps explain why underdiagnosis and undertreatment persist even when services exist. Depression care therefore has to treat stigma as an access barrier, not merely as an attitude problem.

Access interventions should therefore extend beyond specialist treatment and reach the settings where disclosure, referral, and early support actually occur. Samari et al. (2022) argue that public health programs should improve awareness and support among family and friends so that young people with depressive disorders can seek help earlier. At the health-system level, Chodavadia et al. (2023) similarly recommend stronger psychiatric resources, better general-practitioner mental health competence, peer support, and stigma-reduction efforts. These recommendations are not a substitute for individualized treatment; they make treatment more reachable. They also need cultural fit, because workforce capacity in mental health cannot simply be imported into settings where mental illness carries local meanings and barriers (Chodavadia et al., 2023). Practical stigma reduction should therefore combine family education, peer support, primary-care capacity, and culturally grounded professional training.

Conclusion

Depression cannot be understood or addressed well when its causes, treatment challenges, and stigma barriers are treated as separate problems. The evidence considered in this essay points to a condition shaped by stress, social disadvantage, trauma, clinical complexity, comorbidity, and unequal access to care. It also shows that treatment must extend beyond prescribing a first medication, because many people need accurate diagnosis, adequate trials, psychotherapy, stepped treatment decisions, or stronger options for treatment-resistant depression. At the same time, prevention and early detection matter because many people experience symptoms long before they receive formal help. Stigma makes that delay worse by discouraging disclosure and weakening the informal support networks that often determine whether someone seeks care. A stronger response to depression therefore requires an integrated approach: reduce risk where possible, identify symptoms earlier, individualize treatment, expand options for difficult cases, and make help-seeking socially safer.